|
| 33360855 | Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma. | Eur J Cancer | 2021 |
| 33826614 | Identifying treatment options for BRAFV600 wild-type metastatic melanoma: A SU2C/MRA genomics-enabled clinical trial. | PLoS One | 2021 |
| 33824031 | A Living, Interactive Systematic Review and Network Meta-analysis of First-line Treatment of Metastatic Renal Cell Carcinoma. | Eur Urol | 2021 |
| 33678522 | Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial. | Eur Urol | 2021 |
| 33845460 | NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021. | J Natl Compr Canc Netw | 2021 |
| 32196516 | Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations. | PLoS One | 2020 |
| 31750751 | Hospitalization and emergency department utilization in patients with advanced melanoma receiving pembrolizumab versus ipilimumab plus nivolumab in US academic centers. | J Med Econ | 2020 |
| 32023525 | NCCN Guidelines Insights: Uveal Melanoma, Version 1.2019. | J Natl Compr Canc Netw | 2020 |
| 32823698 | A Phase II Study of Glembatumumab Vedotin for Metastatic Uveal Melanoma. | Cancers (Basel) | 2020 |
| 32405921 | Health-related quality of life (QoL) in patients with advanced melanoma receiving immunotherapies in real-world clinical practice settings. | Qual Life Res | 2020 |
| 32233107 | Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma. | BJU Int | 2020 |
| 29076867 | Patient and Oncology Nurse Preferences for the Treatment Options in Advanced Melanoma: A Discrete Choice Experiment. | Cancer Nurs | 2019 |
| 31856918 | The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC). | J Immunother Cancer | 2019 |
| 30892627 | Drug-associated vasculitis occurring after treatment with pembrolizumab. | Rheumatology (Oxford) | 2019 |
| 30959471 | Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2019 |
| 30615010 | Inositol hexaphosphate plus inositol induced complete remission in stage IV melanoma: a case report. | Melanoma Res | 2019 |
| 30686076 | Desmoplastic melanoma: a brief review and the efficacy of immunotherapy. | Expert Rev Anticancer Ther | 2019 |
| 29044496 | NCCTG N0879 (Alliance): A randomized phase 2 cooperative group trial of carboplatin, paclitaxel, and bevacizumab⿿±⿿everolimus for metastatic melanoma. | Cancer | 2018 |
| 29867230 | Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. | Nat Med | 2018 |
| 30021908 | Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic Melanoma. | Clin Cancer Res | 2018 |
| 30291359 | Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. | Nat Med | 2018 |
| 30345423 | Adjuvant Antiangiogenic Agents in Post-nephrectomy Renal Cell Carcinoma: A Systematic Review and Meta-analysis. | Eur Urol Oncol | 2018 |
| 30510087 | Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab. | Clin Cancer Res | 2018 |
| 30407098 | Factors associated with immunotherapy selection in patients with advanced melanoma. | Immunotherapy | 2018 |
| 29549898 | Sentinel lymph node biopsy in Merkel cell carcinoma: The Mayo Clinic experience of 150 patients. | Surg Oncol | 2018 |
| 29468108 | Nivolumab in Renal Cell Carcinoma: Current Trends and Future Perspectives. | J Kidney Cancer VHL | 2018 |
| 29685882 | Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab. | Clin Cancer Res | 2018 |
| 29623256 | Association Between Programmed Death-Ligand 1 Expression and the Vascular Endothelial Growth Factor Pathway in Angiosarcoma. | Front Oncol | 2018 |
| 29623210 | New-onset insulin-dependent diabetes due to nivolumab. | Endocrinol Diabetes Metab Case Rep | 2018 |
| 29283791 | Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma. | J Clin Oncol | 2018 |
| 29320474 | High response rate to PD-1 blockade in desmoplastic melanomas. | Nature | 2018 |
| 27771244 | A Study of Combination Bicalutamide and Raloxifene for Patients With Castration-Resistant Prostate Cancer. | Clin Genitourin Cancer | 2017 |
| 30190917 | Utility of ipilimumab in melanoma patients who progress on anti-PD-1 therapy. | Melanoma Manag | 2017 |
| 30761385 | Molecular Modeling and Functional Analysis of Exome Sequencing-Derived Variants of Unknown Significance Identify a Novel, Constitutively Active FGFR2 Mutant in Cholangiocarcinoma. | JCO Precis Oncol | 2017 |
| 28259541 | Nivolumab treatment for advanced renal cell carcinoma: Considerations for clinical practice. | Urol Oncol | 2017 |
| 28214657 | Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma. | Eur J Cancer | 2017 |
| 28327121 | BAP1 and PBRM1 in metastatic clear cell renal cell carcinoma: tumor heterogeneity and concordance with paired primary tumor. | BMC Urol | 2017 |
| 28396509 | Clinical Features of Acquired Resistance to Anti-PD-1 Therapy in Advanced Melanoma. | Cancer Immunol Res | 2017 |
| 29028788 | Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program. | J Immunother | 2017 |
| 28976794 | Multicenter Validation of Enhancer of Zeste Homolog 2 Expression as an Independent Prognostic Marker in Localized Clear Cell Renal Cell Carcinoma. | J Clin Oncol | 2017 |
| 28950298 | Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study. | Ann Oncol | 2017 |
| 28975018 | Comprehensive Genomic Profiling of a Rare Thyroid Follicular Dendritic Cell Sarcoma. | Rare Tumors | 2017 |
| 28591094 | Non-clear cell renal cell carcinomas: biological insights and therapeutic challenges and opportunities. | Clin Adv Hematol Oncol | 2017 |
| 28660171 | The Feasibility and Safety of Surgery in Patients Receiving Immune Checkpoint Inhibitors: A Retrospective Study. | Front Oncol | 2017 |
| 28860722 | Patient and oncologist preferences for attributes of treatments in advanced melanoma: a discrete choice experiment. | Patient Prefer Adherence | 2017 |
| 27939400 | Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. | Lancet | 2017 |
| 27899233 | Clear Cell Type A and B Molecular Subtypes in Metastatic Clear Cell Renal Cell Carcinoma: Tumor Heterogeneity and Aggressiveness. | Eur Urol | 2017 |
| 27993815 | Differential gene expression profiling of matched primary renal cell carcinoma and metastases reveals upregulation of extracellular matrix genes. | Ann Oncol | 2017 |
| 26073078 | High-resolution profiling of histone h3 lysine 36 trimethylation in metastatic renal cell carcinoma. | Oncogene | 2016 |
| 28723536 | Correlation Between Molecular Subclassifications of Clear Cell Renal Cell Carcinoma and Targeted Therapy Response. | Eur Urol Focus | 2016 |